Publications

BibTex format

@article{Copland:2021:10.1016/S1470-2045(21)00033-4,
author = {Copland, E and Canoy, D and Nazarzadeh, M and Bidel, Z and Ramakrishnan, R and Woodward, M and Chalmers, J and Teo, KK and Pepine, CJ and Davis, BR and Kjeldsen, S and Sundstrom, J and Rahimi, K},
doi = {10.1016/S1470-2045(21)00033-4},
journal = {The Lancet Oncology},
pages = {558--570},
title = {Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis},
url = {http://dx.doi.org/10.1016/S1470-2045(21)00033-4},
volume = {22},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundSome studies have suggested a link between antihypertensive medication and cancer, but the evidence is so far inconclusive. Thus, we aimed to investigate this association in a large individual patient data meta-analysis of randomised clinical trials.MethodsWe searched PubMed, MEDLINE, The Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from Jan 1, 1966, to Sept 1, 2019, to identify potentially eligible randomised controlled trials. Eligible studies were randomised controlled trials comparing one blood pressure lowering drug class with a placebo, inactive control, or other blood pressure lowering drug. We also required that trials had at least 1000 participant years of follow-up in each treatment group. Trials without cancer event information were excluded. We requested individual participant data from the authors of eligible trials. We pooled individual participant-level data from eligible trials and assessed the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), β blockers, calcium channel blockers, and thiazide diuretics on cancer risk in one-stage individual participant data and network meta-analyses. Cause-specific fixed-effects Cox regression models, stratified by trial, were used to calculate hazard ratios (HRs). The primary outcome was any cancer event, defined as the first occurrence of any cancer diagnosed after randomisation. This study is registered with PROSPERO (CRD42018099283).Findings33 trials met the inclusion criteria, and included 260447 participants with 15012 cancer events. Median follow-up of included participants was 4·2 years (IQR 3·0–5·0). In the individual participant data meta-analysis comparing each drug class with all other comparators, no associations were identified between any antihypertensive drug class and risk of any cancer (HR 0·99 [95% CI 0·95–1·04] for ACEIs; 0·96 [0·92&nda
AU  - Copland,E
AU  - Canoy,D
AU  - Nazarzadeh,M
AU  - Bidel,Z
AU  - Ramakrishnan,R
AU  - Woodward,M
AU  - Chalmers,J
AU  - Teo,KK
AU  - Pepine,CJ
AU  - Davis,BR
AU  - Kjeldsen,S
AU  - Sundstrom,J
AU  - Rahimi,K
DO  - 10.1016/S1470-2045(21)00033-4
EP  - 570
PY  - 2021///
SN  - 1213-9432
SP  - 558
TI  - Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
T2  - The Lancet Oncology
UR  - http://dx.doi.org/10.1016/S1470-2045(21)00033-4
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000637971400029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S1470204521000334?via%3Dihub
UR  - http://hdl.handle.net/10044/1/89099
VL  - 22
ER  -

Download

Emeritus ProfessorKimFox

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)